Dengue Envelope-2 32kDa

Dengue fever is a mosquito-borne viral infection caused by one of four closely related viruses, known as serotypes, belonging to the genus Flavivirus and the family Flaviviridae. These serotypes are referred to as DENV-1, DENV-2, DENV-3, and DENV-4. Dengue is prevalent in tropical and subtropical regions around the world, with a significant impact on public health.

Among the four serotypes, DENV-2 is one of the most studied due to its association with severe forms of dengue, such as dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The virus is transmitted to humans through the bites of infected female mosquitoes, primarily of the species Aedes aegypti and Aedes albopictus.

The dengue virus is an enveloped virus with a single-stranded RNA genome. The viral envelope contains two major structural proteins: the envelope (E) protein and the membrane (M) protein. The E protein is responsible for virus attachment, entry into host cells, and fusion of the viral and cellular membranes.

The recombinant Dengue Virus Subtype 2 Envelope 32kDa protein is a laboratory-produced version of the E protein from DENV-2. This recombinant protein is typically produced in Escherichia coli (E. coli) and includes amino acids 45-297 of the E protein, which encompasses domains I and II of the envelope protein .

The recombinant protein is produced by inserting the gene encoding the desired portion of the E protein into E. coli. The bacteria then express the protein, which can be harvested and purified using chromatographic techniques. The purified protein is often fused to a 6xHis tag to facilitate purification and detection .

The recombinant Dengue Virus Subtype 2 Envelope 32kDa protein has several important applications in research and diagnostics:

• Immunoassays: It is used in various immunoassays to detect antibodies against DENV-2 in patient samples. This is crucial for diagnosing dengue infections and for epidemiological studies.
• Vaccine Development: The protein is used in the development of dengue vaccines, as it can elicit an immune response in the host.
• Antibody Production: It is used to generate specific antibodies against the DENV-2 E protein, which can be used in research and diagnostic applications.

The recombinant protein is stable at 4°C for up to one week but should be stored below -18°C for long-term storage to prevent degradation. It is important to avoid freeze-thaw cycles to maintain the protein’s integrity .